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Depression is common in cancer patients, and this often remains undetected and untreated. Depression has been associated with
poorer quality of life, in addition to increased impairment of immune response and poorer survival in cancer patients. Previous
systematic reviews and meta-analyses of the efficacy of interventions for cancer patients with depression have failed to distinguish
between caseness for depression and depressive symptoms. The findings from this systematic review show that there is limited trial
data on the efficacy of prescribed antidepressants in reducing the incidence of major depression and depressive symptoms in cancer
patients. Contrary to previous reviews that failed to distinguish between depressive symptoms and depression, this review found very
little data from clinical trials (without the possibility of confounding factors) to demonstrate that psychotherapeutic interventions are
effective in reducing depression in cancer patients. A number of small-scale, single-centre trials indicated that psychotherapeutic
interventions (especially cognitive behavioural therapy) can have effects on depressive symptoms in cancer patients. However, given
the methodological limitations of studies to date, lack of evidence should not be interpreted as implying lack of efficacy. In conclusion,
there is a need for adequately powered studies of pharmacological and psychotherapeutic studies, which are targeted at cancer
patients with a diagnosis of depression and include monitoring of the use of other pharmacological/psychotherapeutic and
complementary and alternative medicine interventions.
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Studies have reported up to 58% of cancer patients as having
depressive symptoms and up to 38% as having major depression
(Massie, 2004). Depression may be particularly difficult to detect in
patients suffering from cancer, especially those with terminal
illness, and is difficult to distinguish from ‘appropriate sadness’
related to cancer diagnosis, treatment and the approach of end of
life (Lloyd-Williams, 2000; Bailey et al, 2005). There are also
difficulties in deciding which somatic symptoms may be attribu-
table to cancer and its consequences, and which may be due to
depression (Lloyd-Williams, 2001; Bailey et al, 2005). Psychologi-
cal distress, including adjustment problems, anxiety and depres-
sion, typically occurs at many points along the cancer trajectory,
and may be exacerbated by physical pain, the effects of treatment,
family difficulties, financial worries, etc. The importance of
detecting and treating depressive illness in cancer patients lies
not only in the relief of psychological distress and its impact on
quality of life but also on consequent health service and societal
costs. In addition, depression has been associated with increased
impairment of immune response (Andersen et al, 1998; Newport
and Nemeroff, 1998; Reiche et al, 2004) and poorer survival
(Buccheri, 1998; Faller et al, 1999; Watson et al, 1999; Faller and
Bulzebruck 2002; Herjl et al, 2003; Goodwin et al, 2004).
Psychosocial needs are often inadequately addressed by cancer
services, and depression is frequently unrecognised (Newport and
Nemeroff, 1998; Passik et al, 1998; Petito and Evans, 1998; Lloyd-
Williams, 2000; Sharpe et al, 2004; Somerset et al, 2004). Clinical
practice guidelines for the psychosocial care of cancer patients are
available in some countries, such as in the USA and Australia
(Turner et al, 2005). The National Institute for Clinical Evidence
guidelines for the management of depression in primary and
secondary care in the UK propose that screening for depression
should be undertaken in primary-care and general hospital
settings for high-risk groups, which include those with significant
physical illnesses (NICE, 2004).
There have been three recent systematic reviews (Barsevick et al,
2002; Newell et al, 2002; Uitterhoeve et al, 2004) and two meta-
analyses (Devine and Westlake, 1995; Sheard and Maguire, 1999)
of psychotherapeutic interventions for patients with cancer and
depression/depressive symptoms, the results of which provide
broad support for such interventions. In their meta-analysis of 98
studies, Devine and Westlake (1995) concluded that psychoeduca-
tional care is of benefit to adults with cancer and depression.
Likewise, Barsevick et al’s (2002) systematic review of 36 studies
concluded that psychoeducational interventions reduce depressive
symptoms in patients with cancer, and that behaviour therapy or
counselling alone or in combination with cancer education is
beneficial. However, Sheard and Maguire (1999) in their meta-
analysis of 20 trials concluded that preventative psychological
interventions in cancer patients do not have a clinical effect upon
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sdepression. Based on a systematic review of 15 randomised
controlled trials, Newell et al (2002) made tentative recommenda-
tions about the medium-term benefit of group therapy and the
long-term benefits of education and structured counselling.
Uitterhoeve et al’s (2004) systematic review of 13 trials concluded
that psychosocial interventions had positive effects on patients
with advanced cancer and depression.
In addition, a meta-analysis by Meyer and Mark (1995) reported
on the effects of psychosocial interventions with adult cancer
patients in terms of emotional adjustment, which involved
measures of such constructs as mood state, fear and anxiety,
depression, denial or repression, self-esteem and distress.
Although the study did not present findings on efficacy exclusively
in terms of depression/depressive symptoms, it found that
psychosocial interventions have positive effects on emotional
adjustment. There were no significant differences found between
types of interventions (behavioural interventions, nonbehavioural
counselling and therapy, informational and educational methods,
organised social support provided by other patients and other
nonhospice interventions). Even so, the authors stated that it
would be premature to conclude that there were no differences
between treatment categories given the possible confounds.
However, none of these systematic reviews and meta-analyses
distinguished between the presence of depressive symptoms and
caseness for depression in cancer patients, so limiting their
applicability to everyday clinical practice.
There have been no systematic reviews or meta-analyses to date
published on the efficacy of antidepressant treatments for cancer
patients with depression.
The aim of the following study, therefore, was to systematically
review the efficacy of psychotherapeutic and antidepressant
interventions for cancer patients with depression/depressive
symptoms in terms of (i) reduction in depressive symptoms, (ii)
reduction in caseness of clinical depression and (iii) adverse
effects.
MATERIALS AND METHODS
We undertook a systematic review of randomised controlled trials
of pharmacological and psychotherapeutic interventions for cancer
patients with depression/depressive symptoms. The method was
based on established guidelines for conducting systematic reviews
(Chalmers and Haynes, 1994; Mulrow, 1994; Oxman, 1994).
Search strategy
References were retrieved by manual searches and through
searching electronic databases. The following electronic databases
were searched for years 1995–2005 for psychotherapeutic inter-
ventions and 1960–2005 for pharmacological interventions:
PubMed, CINAHL, Cochrane Library databases DARE, CDSR,
CCTR and PsycARTICLES. Manual searches were conducted and
relevant references retrieved from those listed in key papers,
reports, theses and dissertations. Box 1 provides the search
strategy terms.
Inclusion criteria
The criteria for selecting studies were randomised controlled trials
of pharmacological and psychotherapeutic interventions for
depression in cancer patients, published in English. Participants
were either adult cancer patients with depression or depressive
symptoms receiving a pharmacological or psychotherapeutic
intervention for depression/depressive symptoms. Studies investi-
gating the efficacy of psychotherapeutic interventions in the
presence of pharmacological therapy (or vice versa) were excluded,
as were those evaluating the efficacy of complementary and
alternative (CAM) medicine (including meditation) or informa-
tion/education strategies.
Data extraction and synthesis
Data extraction was completed independently by the reviewers
(SW) and (JD) and checked through for accuracy. Data were
gathered using a data extraction form (Appendix A). The main
outcomes were either depressive symptoms or diagnosed clinical
depression measured by a separate scale or as part of a composite
outcome measure. Study quality was assessed with the Methodo-
logical Quality Instrument (Appendix A) developed by Cho and
Bero (1994). Studies were assessed as being of low methodological
quality if they failed to meet the minimum requirements on each
of the following aspects of study design: adequacy of sample size,
randomisation, blinding, method of allocation concealment, clear
description of treatment, representative source of subjects, use of
diagnostic criteria, number of and reasons for withdrawal from
intervention and how dealt with in the analysis, outcome measures
described clearly, use of validated instruments, and steps taken to
control for possible confounding factors.
RESULTS
Study inclusion and characteristics
Figure 1 shows the numbers of studies yielded by the search
strategy. In all, 29 papers reporting pharmacological studies and 63
reporting psychotherapeutic interventions were identified as
potentially relevant and were carefully read. Of these, we excluded
65 because they did not meet the inclusion criteria, and a further
two were excluded because they were not strictly randomised
controlled trials (Holland et al, 1998; Kissane et al, 2003) and one
because it failed to measure baseline levels of depressive symptoms
(Stiegelis et al, 2004). This left a total of 24 studies (Table 1), of
which six were trials of pharmacological treatments and 18 were of
psychotherapeutic interventions.
Pharmacological studies
The six pharmacological studies were randomised placebo-
controlled trials conducted in the United States of America
(n¼4) (Musselman et al, 2001; Fisch et al, 2003; Morrow et al,
2003; Roscoe et al, 2005) and Belgium (n¼2) (Razavi et al, 1996;
Box 1 Search strategy terms
Search terms were taken from known articles relevant to the review and the Medical Subject Headings (MeSH) thesaurus of the US National Library of Medicine
(NLM). The search terms included: ‘Depression’; ‘Depressive Disorder’; ‘Depressive Disorders’; ‘Disorder, Depressive’; ‘Disorders, Depressive’; ‘Neurosis, Depressive’; ‘Depressive
Neuroses’; ‘Depressive Neurosis’; ‘Neuroses, Depressive’; ‘Melancholia’; ‘Melancholias’; ‘Unipolar Depression’; ‘Depression, Unipolar’; ‘Depressions, Unipolar’; ‘Depression,
Endogenous’; ‘Depressions, Endogenous’; ‘Endogenous Depression’; ‘Endogenous Depressions’; ‘Depressive Syndrome’; ‘Depressive Syndromes’; ‘Syndrome, Depressive’;
‘Syndromes, Depressive’; ‘Depression, Neurotic’; ‘Depressions, Neurotic’;‘ Neurotic Depression’; ‘Neurotic Depressions’; ‘Depressions’;‘ Depressive Symptoms’; ‘Depressive
Symptom’; ‘Symptom, Depressive’; ‘Symptoms, Depressive’; ‘Emotional Depression’; ‘Depression, Emotional’; ‘Depressions, Emotional’; ‘Psychiatric Morbidity’; ‘Psychological
Morbidity’; ‘Cancer’; ‘Neoplasms’; ‘Neoplasms, Second Primary’; ‘Hypothalamic Neoplasms’; ‘Brain Neoplasms’; ‘Brain Stem Neoplasms’; ‘Head and Neck Neoplasms’; ‘Spinal
Cord Neoplasms’; ‘Meningeal Neoplasms’; ‘Urologic Neoplasms’; ‘Cerebellar Neoplasms’; ‘Supratentorial Neoplasms’; ‘Unrogenital Neoplasms’; ‘Sigmoid Neoplasms’;
‘Infratentorial Neoplasms’; ‘Cerebral Ventricle Neoplasms’; ‘Testicular Neoplasms’; ‘Pharyngeal Neoplasms’; ‘Pelvic Neoplasms’; ‘Ovarian Neoplasms’; ‘Breast Neoplasms’;
‘Antidepressive Agents’;‘ Antidepressive Agents – adverse effects’; ‘Serotonin Uptake Inhibitors’; ‘Fluoxetine’; ‘Cognitive Therapy’; ‘Randomised Controlled Trials’
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sVan Heeringen and Zivkov, 1996). The mean sample size of
intervention and control groups was 83 (range 20–277 patients)
and 83 (range 20–272 patients), respectively. The average age of
patients ranged from 50 to 61 years. Between half to 100% of
participants were female. Three studies were multicentre trials
(Razavi et al, 1996; Fisch et al, 2003; Morrow et al, 2003) and three
were single-centre trials (Van Heeringen and Zivkov, 1996;
Musselman et al, 2001; Roscoe et al, 2005).
Methodological quality The methodological quality of these trials
is summarised in Table 2. The sample size exceeded 100 patients in
two of the six (33%) trials (Fisch et al, 2003; Morrow et al, 2003).
The method of randomisation to groups was sufficiently well
described in all studies, but the method of allocation concealment
was adequately described in only four trials (Razavi et al, 1996;
Musselman et al, 2001; Fisch et al, 2003; Roscoe et al, 2005).
Blinding of investigators was reported in five trials (Razavi et al,
1996; Van Heeringen and Zivkov, 1996; Musselman et al, 2001;
Fisch et al, 2003; Roscoe et al, 2005) and blinding of subjects in all
trials. All studies provided a clear description of the intervention,
had a representative source of subjects and provided the number
and reasons for withdrawals. Dropout rates for intervention and
controls ranged from 0 to 56%. Three trials stated that intention-
to-treat analyses were used to deal with patients who were lost to
follow-up (Razavi et al, 1996; Van Heeringen and Zivkov, 1996;
Musselman et al, 2001).
Two trials selected subjects on the basis of a depressive disorder
using Diagnostic and Statistical Manual of Mental Disorders, third
edition (DSM-III) criteria (Razavi et al, 1996; Van Heeringen and
Zivkov, 1996); one selected patients who were to receive high-dose
alpha therapy (which has been associated with symptoms of major
depression) (Musselman et al, 2001). Three trials reported on the
efficacy of the pharmacological treatment in terms of caseness for
depression (Razavi et al, 1996; Musselman et al, 2001; Roscoe et al,
2005) with the other three trials reporting on change in the level of
depressive symptoms as indicated by scores on questionnaires
(Van Heeringen and Zivkov, 1996; Fisch et al, 2003; Morrow et al,
2003). All outcome measures were clearly described and were valid
and reliable (Table 1).
Five trials investigated the efficacy of selective serotonin
reuptake inhibitors with three investigating paroxetine (Musselman
et al, 2001; Morrow et al,2 0 0 3 ;R o s c o eet al, 2005) and two
fluoxetine (Razavi et al,1 9 9 6 ;F i s c het al, 2003), while the
remaining study investigated the tricyclic antidepressant mianserin
(Van Heeringen and Zivkov, 1996). All six trials avoided/monitored
pharmacological cointerventions by trial design. None of the six
studies reported avoiding or monitoring the use of potentially
confounding psychotherapeutic or CAM cointerventions by subjects
during the study periods.
Effectiveness and tolerability
Depression: One trial found paroxetine effective in reducing
major depression in cancer patients with malignant melanoma
who were to receive high-dose interferon alpha therapy (Musselman
et al, 2001). Major depression developed in 11% (two of 18) of the
paroxetine and 45% (nine of 20) of the placebo group, and 5% of
paroxetine compared to 35% of the placebo group had to
discontinue interferon alpha because of severe depressive distress.
In terms of tolerability, retinal haemorrhages developed in three
patients (severely in one patient) who were taking paroxetine. The
sample size was only 40 patients, but no subjects withdrew from
the study.
Another trial found paroxetine to be effective in reducing
caseness for depression in breast cancer patients receiving
chemotherapy (Roscoe et al, 2005). At final follow-up (cycle 4 of
chemotherapy), only four of the original 13 patients (31%) in the
paroxetine group who had baseline depression (scoring greater
than 19 on the Center for Epidemiological Studies Depression
scale) had scores above the cutoff, while all 13 (100%) of the
initially depressed patients in the placebo group remained above
the threshold. Dropout rates were comparable for intervention and
controls (25 and 21%, respectively).
Fluoxetine was not effective in reducing caseness for depression
in a trial that included patients with breast, gynaecological or
haematological cancer who presented with major depressive
disorder (Razavi et al, 1996). The successful response rate (defined
by Hospital Anxiety and Depression Scale (HADS) score lower
than 8 after 5 weeks of treatment) was not significantly higher
(11%) in the intervention group than the placebo group (7%). Side
effects between groups were not significantly different, although
there was a trend towards digestive and neuropsychiatric adverse
events in the intervention group. There were, however, signifi-
cantly more dropouts from the intervention group (33%)
compared with controls (15%) (P¼0.04).
Depressive symptoms: Paroxetine was found to be effective in
reducing depressive symptoms in breast, lung, haematological,
gynaecological and gastrointestinal cancer patients who reported
fatigue at their second chemotherapy cycle (Morrow et al, 2003).
Dropout rates were comparable for intervention and controls
Total pharmacological
studies yielded (n = 60)
Total included studies
(n = 24)
Total psychotherapeutic
studies yielded (n = 104)
Possible inclusion
(scrutinised in detail)
(n = 29)
Possible inclusion
(scrutinised in detail)
(n = 63)
Included studies
(n = 6)
Included studies
(n = 18)
Not meeting inclusion
criteria (n =31)
Not meeting inclusion
criteria (n =41)
Not meeting inclusion
criteria (n =43)
Not meeting inclusion
criteria (n =22)
Excluded (not strictly
RCT) (n = 1)
Excluded (e.g.not
strictly RCT) (n = 2)
(n = 7) (n = 20)
Figure 1 Number of studies yielded by search strategy.
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sTable 1 Characteristics of included studies (n¼24)
Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
Pharmacological studies (cancer various sites)
Morrow et al (2003), USA
Design: Randomised placebo-controlled
trial
Random allocation to treatment groups:
YES
Concealed treatment allocation:
UNCLEAR
Blinding of investigators: NO
Blinding of subjects: YES
Known confounders accounted for by
study design: PARITIAL
Attrition of subjects and reasons: YES
Dropout rate: I¼12%, C¼14%
549 cancer patients with a
diagnosis of any type of
cancer reporting fatigue
at their second chemotherapy
cycle
Mean age (years) (s.d.):
I¼56.5 (12.6)
C¼56.3 (12.3)
Gender:
I¼80% female
C¼71% female
I¼SSRI paroxetine
(20mgday
 1) for 8 weeks
(n¼277)
C¼placebo for 8 weeks
(n¼272)
Depressive symptoms CES-D
and DD
Assessments performed at
baseline (cycle 2 of
chemotherapy), cycle 3 and
cycle 4
At conclusion (cycle 4) the paroxetine
group had a significantly lower mean level
of depression than placebo group as
measure on the CES-D (P¼0.003) and
DD (Po0.001)
Mean decrease in CES-D score from
baseline to end point was 18.9% in the
paroxetine group and 6.3% in the control
group
Tolerability: not reported
Not reported
Fisch et al (2003), USA
Design: Randomised placebo-controlld
trial
Random allocation to treatment groups:
YES
Concealed treatment allocation: YES
Blinding of investigators: YES
Blinding of subjects: YES
Known confounders accounted for by
study design: PARTIAL
Attrition of subjects and reasons: YES
Dropout rate: I¼54%, C¼44%, NS
163 patients with an
advanced solid tumour and
expected survival between 3
and 24 months
Mean age (years):
I¼61
C¼59
Gender:
I¼45% female
C¼55% female
I¼SSRI fluoxetine
(20mgday
 1) for 12 weeks
(n¼83)
C¼placebo for 12 weeks
(n¼80)
Depressive symptoms: 11-item
BZSDS
Assessments performed at
baseline and every 3 to 6 weeks
thereafter. Patients were
assessed for 12 weeks and
complete assessment involved
three to five sessions of data
collection. After 12 weeks,
patients were given option to
continue the study drug blinded
for up to 9 months
The fluoxetine group improved significantly
compared with placebo on depression
scale (P¼0.0005)
Mean decrease in BZSDS score from
baseline to end point was 13.5% in the
fluoxetine group and 2.4% in the control
group
Tolerability:
9 (33%) of 27 patients in fluoxetine arm
reported one or more episodes of emesis
at study completion visit compared with
two (4.6%) of 43 patients receiving placebo
(P¼0.01) although there were significantly
more fluoxetine patients receiving radiation
therapy
Not reported
Pharmacological studies (cancer various sites)
Razavi et al (1996), Belgium
Design: Experimental randomised
placebo-controlled trial
Random allocation to treatment groups:
YES
Concealed treatment allocation: YES
Blinding of investigators: YES
Blinding of subjects: YES
Known confounders accounted for by
study design: PARTIAL
Attrition of subjects and reasons: YES
Dropout rate: I¼33%, C¼15%
(P¼0.04)
91 cancer patients with a
major depressive disorder
or an adjustment disorder
as defined by DSM-III
Patients with score of 13 or
higher on the HADS at
start
Mean age (years) (s.d.):
I¼53.2 (11.4)
C¼52.6 (11.3)
Gender: I¼77% female
C¼82% female
After a single-blind placebo
period of 1 week patients
(to exclude early placebo
responders and false-positive
cases for depression) were
randomised to:
I¼SSRI fluoxetine
treatment (20mgday
 1)
(n¼45)
C¼Placebo (n¼46)
Depression/depressive
symptoms
MADRS, HADS
Measured at baseline, 1, 3 and
5 weeks after the intervention
HADS, NS
Tolerability: Frequencies of side effects
between groups was not significantly
different
Digestive and neuropsychiatric types of
adverse events were more frequent in the
intervention group although this was not
significant
Caseness, NS:
The successful response rate
defined by HADS score lower
than 8 after 5 weeks of
treatment was not significantly
higher (11%) in the intervention
group than the placebo group
(7%)
Pharmacological studies (skin cancer)
Musselman et al (2001), USA
Design: Randomised placebo-controlled
trial
40 patients with malignant
melanoma who were to
receive high-dose interferon
Interferon alpha has been
associated with symptoms
that overlap with those
Depression:
HAM-D21, CDS, DSM-IV
Assessment performed at
Tolerability: After 12 weeks, small
reversible retinal haemorrhages developed
in two patients and one patient had more
Paroxetine treatment
significantly reduced the
incidence of major depression
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Clinical StudiesTable 1 (Continued)
Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
Random allocation to treatment groups:
YES
Concealed treatment allocation: YES
Blinding of investigators: YES
Blinding of subjects: YES
Known confounders accounted for by
study design: PARTIAL
Attrition of subjects and reasons: YES
Dropout rate: I¼0%, C¼0%
alpha therapy
Mean age (years) (s.d.):
I¼52.8 (7.6)
C¼50.1 (13.4)
Gender:
I¼50% female
C¼50% female
found in major depression
I¼SSRI paroxetine:T w o
weeks before the initiation of
interferon alpha therapy SSRI
Paroxetine (10mgday
 1 1
tablet) for one week
(20mgday
 1 2 tablets) for
one week. Four weeks after
the initiation of paroxetine
therapy the dosage could
be increased up to
40mgday
 1 4 tablets) (n¼20)
C¼placebo therapy (n¼20)
baseline and at regularly
scheduled intervals after the
initiation of interferon alpha
therapy for the first 12 weeks
of a planned 48-week
treatment period.
severe retinal haemorrhages with
associated irreversible loss of vision. All
three patients were taking paroxetine.
Retinal haemorrhage is a rare side effect of
paroxetine and high rates of retinal
complications occur in patients treated with
interferon alpha. Paroxetine significantly
decreased the likelihood that interferon
alpha therapy would be discontinued
because of severe depression or related
neurotoxic effects (P¼0.03)
(P¼0.04)
Symptoms consistent with
major depression developed in
two of the 18 (11%) patients in
paroxetine group and nine of
the 20 (45%) patients in the
placebo group
HAM-D21 (P¼0.01)
Pharmacological studies (breast cancer)
Roscoe et al (2005), USA
Design: Randomised placebo-controlled
trial
Random allocation to treatment groups:
YES
Concealed treatment allocation: YES
Blinding of investigators: YES
Blinding of subjects: YES
Known confounders accounted for by
study design: PARTIAL
Attrition of subjects and reasons: YES
Dropout rate I¼25%, C¼21%
94 female breast cancer
patients receiving at least
four cycles of chemotherapy
and not undergoing
concurrent radiation or
interferon treatments
Mean age (years) (s.d.):
I¼52.2 (9.3)
C¼52.2 (10.2)
I¼SSRI paroxetine
(20mgday
 1) for four cycles
of chemotherapy (n¼44)
C¼placebo for four cycles
of chemotherapy (n¼50)
Depression/depressive
symptoms CES-D and DD
Paroxetine was more effective than
placebo in reducing depressive symptoms
during chemotherapy as measured by the
CES-D (P¼0.006) and the DD (P¼0.07)
Mean decrease in CES-D score from
baseline to end point was 40% in the
paroxetine group and 14% in the control
group
Tolerability: Not reported
By cycle 4, only four of the
original 13 patients in the
paroxetine group who had
baseline CES-D scores greater
than 19 still had scores above
that cutoff point. This compares
to all 13 of the initially
depressed patients in the
placebo group remaining above
threshold.
Van Heeringen and Zivkov (1996),
Belgium
Design: Experimental randomised
placebo-controlled trial
Random allocation to treatment groups:
YES
Concealed treatment allocation:
UNCLEAR
Blinding of investigators: YES
Blinding of subjects: YES
Known confounders accounted for by
study design: PARTIAL
Attrition of subjects and reasons: YES
Dropout rate: I¼21%, C¼56%
(P¼0.014)
55 women with breast cancer
(stage I or stage II without
metastases) with a diagnosis
of depression according to
the DSM-III criteria
Mean age (years) (s.vnd.):
I¼51 (8)
C¼53 (8)
I¼TCA mianserin
treatment: 1 week
30mgday
 1, then
60mgday
 1 (n¼28)
C¼Placebo (n¼27)
Depressive symptoms
HAM-D21
Measured at 14, 28 and
42 days after treatment
There were significantly lower HAM-D21
scores for the mianserin group at 28 days
(P¼0.004) and 42 days (P¼0.004)
Tolerability: No significant differences were
found between numbers of patients
complaining of at least one adverse event at
any assessment point. No clinically relevant
changes were seen in vital signs
Not reported
Psychotherapeutic studies (cancer various sites)
Kuijer et al (2004), The Netherlands
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
59 couples with medical
diagnosis of cancer in one
partner with an estimated
life expectancy of at least 6
months for the ill partner
I¼CBT: brief counselling
program directed at couples
focused on the exchange of
social support and help
between both partners. Five
Depressive symptoms
Psychological distress – CES-D
I¼Once before intervention, 1
week postintervention and 3
months postintervention
Among patients psychological distress
decreased significantly 1 week after the
intervention (Po0.05), ES¼0.55
Mean decrease in CES-D score for patients
from baseline to end point was 31.7%
Not reported
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sTable 1 (Continued)
Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
Concealed treatment allocation:
UNCLEAR
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for by
study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: I¼37.5%, C¼40.7%
Mean age (years) (s.d.):
I¼Patient 50 (12)
C¼Patient 49 (10)
Gender patient:
I¼70% female
C¼68% female
90min sessions led by a
psychologist held biweekly.
The approach was cognitive-
behaviourally oriented
(n¼20)
C¼waiting list group
(n¼19)
I2¼twice before intervention,
1 week postintervention
and 3 months
postintervention
in the experimental group and  7.6%
in the waiting list group
Given et al (2004), USA
Design: Experimental randomised
controlled trial
Random allocation to treatment groups:
YES
Concealed treatment allocation:
UNCLEAR
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for by
study design: NO, cointerventions not
reported
Attrition of subjects and reasons:
attrition, but no reasons given
Dropout rate: I¼32%, C¼27%
237 patients diagnosed
with a solid tumour and
within 56 days of undergoing
a first cycle of chemotherapy
Mean age (years):
I¼59.3
C¼61.2
Gender:
Approx 80% female
I¼CBT: 10 contact (1h
sessions), 20 week
experimental group cognitive
behavioural approach for
symptom management. Each
strategy for addressing a
symptom problem was
evaluated at follow-up with
the patient. If the strategy
had been tried and was
effective it was retained
and if not new strategies
were introduced (n¼118)
C¼conventional care
(n¼119)
Depressive symptoms –
CES-D
Baseline, 10 and 20 weeks
The intervention had a short-term
(10 weeks) but no long-term
(20 weeks) effect on patient
depressive symptoms (ES¼0.25–0.33
at 10 and 20 weeks, respectively)
The intervention was more effective in
lowering depressive symptoms at
10 weeks among patients with higher
levels of baseline symptom severity.
Among patients with high levels of
baseline depression, the intervention
was less successful in lowering
depressive symptoms at 10 weeks
than the conventional care control
group alone
Not reported
Psychotherapeutic studies (cancer various sites)
Rawl et al (2002), USA
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: YES
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: I¼38%, C¼19%
109 patients newly diagnosed
with breast, colon or lung
cancer who were receiving
chemotherapy
Mean age (years) (s.d.):
55.7 (11.9)
Gender:
I¼87% female
C¼73% female
I¼Computer-based
assessment and
individually tailored
care plans: A menu-driven
computer program that
guided clinical assessment,
problem identification,
selection of interventions
and measurement of
outcome. For each
symptom or problem
exhaustive problem-specific
lists of appropriate
interventions were available.
Nurse specialists could
input assessments of
patients’ physical and
psychosocial functioning
(including anxiety and
depression) and symptom
experience. It allowed for
individual tailoring of care
plans. Nurses also provided
Depressive symptoms
CESD-20
Measured at baseline, time 2
midway through intervention
and time 3 one month
postintervention (24 weeks)
Patients who received the intervention
had significantly fewer symptoms
between baseline and time 2.
CESD-20 at time 2 (P¼0.05)
Not reported
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Clinical StudiesTable 1 (Continued)
Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
emotional support and
counselling during each
session (n¼55)
C¼standard care
(n¼54)
McLachlan et al (2001), Australia
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: YES
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: I¼28%, C¼31%
450 cancer patients
The authors stated that
patient demographics were
well balanced in the two arms.
Median age (years) (range):61
(18–92)
Gender:
41% female
I¼Computer-based
assessment and
individually tailored
care plans: A computer-
generated one-page summary
of the questionnaire results
(CNQ, EORTC QLQ-30, BDI)
was made available immediately
for consideration during the
consultation with the doctor.
After discussion with the
doctor and patient the co-
ordination nurse formulated
an individualised management
plan (n¼296)
C¼conventional clinical
encounter (n¼154)
Depression/depressive
symptoms
BDI –short form
Measured at baseline, 2 and 6
months after intervention
For patient subgroup that were moderately
or severely depressed at baseline, significant
reduction in depression at 6 months
(P¼0.001)
At 2 and 6 months, 73 and 90%
of patients who were
moderately or severely
depressed at baseline were still
so, whereas in the intervention
arm, there were 58 and 45%,
respectively
Psychotherapeutic studies (breast cancer)
Evans and Connis (1995), USA
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: 8% overall
78 stage II depressed cancer
patients receiving radiation
treatment
Mean age (years):
I1¼54.2
I2¼53.7
C¼53.8
Gender:
I1¼37% female
I2¼33% female
C¼33% female
I1¼CBT: Cognitive-
behavioural treatment
(8 week) led by a social
worker with more than 10
years of group counselling
experience. Group sessions
lasted 1h per week and had
six to nine participants. The
focus was on cognitive and
behavioural strategies to
reduce maladaptive anxiety
and depression (n¼29)
I2¼Social support: Social
support (8 week) led by a social
worker with more than 10
years of group counselling
experience. Group sessions
lasted 1h per week and had
six to nine participants. The
leader encouraged members
to describe their feelings
about having cancer, to
identify shared problems, to
discuss how these are
handled and to adopt
Depressive symptoms
CES-D and SCL-90-R
measured at baseline, 8 weeks
and 6 months
Subjects who received either cognitive
behavioural or social support group
interventions had significantly lower
CES-D scores than controls at 8 weeks
(Po0.01) and at 6 months social support
group interventions had significantly lower
CES-D scores than controls (Po0.01).
Mean decrease in CES-D score for
patients from baseline to 6 months was
11% for the cognitive behavioural group,
29% for the social support group and
14% in the control group
Not reported
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Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
supportive roles (n¼23)
C¼No treatment control
(n¼26)
Winzelberg et al (2003), USA
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: 19% overall
72 women with primary
breast carcinoma
Mean age (years)
(s.d.): 49.5 (6.2)
There were no baseline
differences between groups
I¼Social support/
education: web-based
psychoeducational support
group, 12 weeks. The program
introduced a new topic related
to breast cancer each week and
the mental health professional
facilitated a discussion on these
topics and related concerns.
On the website participants
were able to read personal
stories from survivors, share
their own experiences and
keep a private web-based
personal journal. Participants
wrote a brief description of
how they were feeling when
they logged on (n¼36)
C¼Wait-list control (n¼36)
Depressive symptoms
CES-D
Measured at baseline and at
end of intervention
(12 weeks)
CES-D (Po0.01), ES¼0.54
Mean decrease in CES-D score for patients
from baseline to 12 weeks was 36% in the
experimental group and 4% in the control
group
Not reported
Psychotherapeutic studies (breast cancer)
Antoni et al (2001), USA
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons:
attrition but not reason: Dropout
rate: 26% overall
100 women newly treated
for stage 0–II breast cancer
Mean age (years) (s.d.):
I¼48.1 (9.0)
C¼52.1 (9.0)
I¼CBT: 10-week group
cognitive behavioural stress
management intervention.
Weekly for ten 2-h sessions.
It included both problem-
focused (e.g. active coping
and planning) and emotion-
focused (e.g. relaxation
training, use of emotional
support) coping strategies
(n¼47)
C¼Education/
information: One-day group
seminar approximately 16–18
weeks postsurgery. To provide
at least some information on all
of the topics covered by the
intervention condition (n¼53)
Depressive symptoms
POMS, CES-D
Measured at baseline,
post-intervention (3 months),
3 months and 9 months
POMS, NS
CES-D In the intervention group the
proportion of women meeting criteria for
moderate levels of depressive symptoms
fell significantly at 3 months
postintervention, 6 months and 12 months
(Po0.04)
Not reported
Goodwin et al (2001), Canada
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
235 women with metastatic
breast cancer who were
expected to survive at
least 3 months
Mean age (years) (s.d.):
I¼CBT: Weekly supportive–
expressive group therapy
(90min sessions) for at least
one year. Groups consisted
of 8–12 women and two
Depressive symptoms
POMS
Measured at baseline
and 4, 8 and 12 months
after randomisation
POMS Depression dejection was
significantly lower in the intervention group
(P¼0.002) 1 year after randomisation
The psychological intervention was
not associated with prolonged survival
Not reported
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Clinical StudiesTable 1 (Continued)
Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
Concealed treatment allocation: YES
Blinding of investigators: YES
Blinding of subjects: NO
Known confounders accounted for by
study design: PARTIAL
Attrition of subjects and reasons: YES
Dropout rate: I¼30%, C¼35%, NS
I¼49.5 (8.4)
C¼51.5 (10.3)
leaders. A monthly 90min
session was provided for
family and friends (n¼158)
C¼Education/
information: Education
materials only. No supportive–
expressive group therapy
intervention (n¼77)
Psychotherapeutic studies (breast cancer)
Classen et al (2001), USA
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: 18% overall
125 women with metastatic
breast cancer
Mean age (years) (s.d.):
I¼52.9 (10.7)
C¼54.0 (10.7)
I¼CBT/education: 1 year
of weekly (90min sessions)
of supportive–expressive
group therapy and educational
materials. The treatment
strategy is to facilitate
discussion of issues that are
uppermost in the patients’
minds rather than imposing
topics to be discussed (n¼64)
C¼Education/
information: Education
materials only (n¼61)
Depressive symptoms
POMS
Measured at baseline and
every 4 months during the
first year
POMS Depression
When follow-up assessments undertaken
within 1 year of the patients’ death
were excluded in the secondary
analyses POMS Depression subscale
was significantly lower for the treatment
group, ES¼0.27
Not reported
Fukui et al (2000), Japan
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: 8% overall
50 women with primary
breast carcinoma
Mean age (years) (s.d.):
I¼52.6 (6.8)
C¼54.3 (7.5)
I¼CBT: Six group sessions of
structured psychosocial
intervention with a cognitive-
behavioural approach. It
included health education,
coping skills training, stress
management and psychological
support (n¼25)
C¼Wait-list control (n¼25)
Depressive symptoms
HADS, POMSMeasured at
baseline, 6 weeks and
6 months
HADS, NS Not reported
Sandgren et al (2000), USA
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
53 women newly
diagnosed with stage I or II
breast cancer
Mean age (years) (s.d.):
51.23 (12.5)
I¼CBT: Individual
psychosocial therapy (cognitive
behavioural) delivered by three
female psychology graduate
students by telephone. There
were a total of ten therapy
sessions (average duration
20–25min) once a week for
4 weeks and then every other
week for six more sessions. The
intervention focused on four
Depressive symptoms
POMS
Measured at baseline, 1, 4
and 10 months
POMS Depression, NS Not reported
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Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
Attrition of subjects and reasons: YES
Dropout rate: 15% overall
areas: providing support,
teaching coping skills, managing
anxiety and stress and helping
to solve patient generated
problems.(n¼24)
C¼No therapy control
(n¼29)
Psychotherapeutic studies (breast cancer)
Edelman et al (1999), Australia
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons:
Attrition but no reasons Dropout
rate: 23% overall
124 women with metastatic
breast cancer
Mean age (years) (range): 50
(29–65)
There were no significant
differences in age between
groups
I¼CBT: Group cognitive
behaviour therapy. Eight weekly
sessions of group CBT followed
by a family night and three
further monthly sessions. The
therapy incorporated the use of
cognitive and behavioural
techniques as well as
encouraging the expression of
feeling and building of group
support (n¼62)
C¼No therapy control
(n¼62)
Depressive symptoms
POMS
Measured at baseline, after
completion of therapy, 3
months and 6 months
After completion of therapy significant
improvement in depressive symptoms
(P¼0.008)
Not reported
Marchioro et al (1996), Italy
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons: NO
36 newly diagnosed women
with non-metastatic breast
cancer assigned to adjuvant
chemotherapy after surgery
Median age (years):
I¼53
C¼52
I¼Counselling/
psychotherapy: Weekly
50min individual cognitive
individual psychotherapy and
bimonthly family counselling
with a psychologist. Cognitive
psychotherapy was aimed at
analysis and relief of major
problems related to cancer
diagnosis and therapy: anxiety
and/or depression, loss of
behavioural and emotional
control, altered cognitive
functioning, social and role
limitations and physiological
symptoms (n¼18)
C¼Standard follow-up
(n¼18)
Depressive symptoms
BDI
Measured at baseline and
after 1, 3, 6 and 9 months
Depression scores improved significantly
over time in the intervention group
(ES¼0.27)
Not reported
McArdle et al (1996), UK
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
272 women undergoing
surgery for breast cancer
Median age (years):
I1¼59
I2¼55
I1¼routine care plus
education/information/
counselling/support from
breast care nurse: routine
care (including information
booklet) plus support from
Depressive symptoms
GHQ-28, HADS
Measured at 1, 3, 6 and 12
months after surgery
Scores were lower in patients offered
support from breast care nurse alone (I1)
GHQ-28 (P¼0.015)
HAD Depression (P¼0.003)
Severe depression (P¼0.072)
Not reported
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Clinical StudiesTable 1 (Continued)
Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons:
YES Dropout rate: 17% overall
I3¼56
C¼57
breast care nurse (information
and counselling) (n¼70)
I2¼routine care plus
education/information/
counselling/support from
voluntary organisation
routine care plus support from
voluntary organisation (offering
three types of support:
information, counselling and
regular group meetings with
fellow cancer suffers) (n¼66)
I3¼routine care plus
education/information/
counselling/support from
nurse and organisation
(n¼69)
C¼routine care from ward
staff (n¼67)
Psychotherapeutic studies (gynaecological cancer)
Burton et al (1995), UK
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons:
Attrition unclear and no reasons
200 women awaiting
mastectomy or sector
mastectomy for breast cancer
Mean age (years):
I1¼61
I2¼62
I3¼64
C¼57
I1¼Counselling/
psychotherapy: Individual
preoperative interview and a
30min brief psychotherapeutic
intervention (n¼50)
I2¼Individual preoperative
interview and a 30min ‘chat’ to
control for the effects of
attention (n¼50)
I3¼preoperative interview
only (n¼50)
C¼routine hospital care
control (n¼50)
Depression, Depressive
symptoms
HADS, GHQ-28, PSE schedule
Measured at baseline, 4 days, 3
months and 1 year after surgery
More control patients were
cases for depression on PSE
criteria at one year than
patients in the experimental
groups (P¼0.037)
Petersen and Quinlivan (2002), Australia
Design: Experimental randomied
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: YES
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: 6% overall
53 patients with
gynaecological cancer
Mean age (years) (s.d.):
I¼63.0 (9.6)
C¼61.2 (13.5)
I¼Counselling/relaxation:
1h relaxation and counselling
interview performed by a
senior medical practitioner
involved in the patient’s care.
The structured interview
consisted of listening to a
tape of relaxation music for
approx. 5min followed by a
series of relaxation exercises
that lasted 20min. Patients
were encouraged to use the
techniques at home if they felt
stressed or anxious. The final
30–35min was spent
Depressive symptoms/
depression HADS GHQ-28
Measured at baseline and six
weeks
The intervention was associated with a
significant reduction in total HADS score
(P¼0.002), reduction in HADS Mild/
moderate Depression subscale (P¼0.02),
and lower GHQ-28 scores (P¼0.03)
No significant difference was found in
the fourth subscale of major depression
HADS score case/noncase
(P¼0.0001)
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sTable 1 (Continued)
Subjects Intervention (n)
Author (date), country of origin
and study quality
I¼Intervention
C¼Control
I¼Intervention
C¼Control
Outcome measures for
depression or depressive
symptoms Results
Caseness for
depression
discussing the patient’s
condition (n¼27)
C¼Patients were provided
with all the normal
postoperative support,
counselling and information
services provided by the
respective hospitals (n¼26)
Psychotherapeutic studies (testicular cancer)
Moynihan et al (1998) , UK
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: YES
Blinding of investigators: YES
Blinding of subjects: NO
Known confounders accounted for by
study design: NO, cointerventions
not reported
Attrition of subjects and reasons: YES
Dropout rate: 7% overall
73 men with newly
diagnosed testicular
cancer
I¼CBT/PST: Adjuvant
psychological therapy which
uses both cognitive and
behavioural approaches
includes strategies such as
problem solving and regaining
control. The intervention
consisted of six individual
sessions each lasting 1h by a
state registered mental health
nurse who was experienced
in caring for patients with
testicular cancer (n¼36)
C¼standard care (n¼37)
Depression/depressive
symptoms
HADS
Measured at baseline 2, 4
and 12 months
HAD Depression scale, NS The proportion of patients
scoring above the threshold on
subscale was not influenced by
adjuvant psychological therapy
Prostate cancer
Weber et al (2004), USA
Design: Experimental randomised
controlled trial
Random allocation to treatment
groups: YES
Concealed treatment allocation: NO
Blinding of investigators: NO
Blinding of subjects: NO
Known confounders accounted for
by study design: PARTIAL
Attrition of subjects and reasons:
YES Dropout rate: 0%
30 men who had recently
undergone a radical
prostatectomy for prostate
cancer
Mean age (years) (s.d.):
I¼57.5 (6.7)
C¼59.7 (6.6)
I¼Social support: Peer
support program – 10 men
who were long term survivors
of prostate cancer received
2h training session to act as
support partners. Each dyad
met eight times during an 8
week period and each dyad
determined the focus and
direction of its own exchanges
(n¼15)
C¼usual care (n¼15)
Depressive symptoms
GDS short versionAssessed
at baseline, 4 weeks and
8 weeks
There was a significant difference in
depression between groups at
4 weeks (P¼0.02) (ES¼0.99), but
no significant difference at 8 weeks
Mean decrease in GDS score for
patients from baseline to 4 weeks
was 88% in the experimental group
and 0% in the control group
Not reported
BZSDS¼Brief Zung Self-Rating Depression Scale; HAM-D21¼21-item Hamilton Depression Rating Scale; SSRI¼selective serotonin reuptake inhibitor; CES-D¼Center for Epidemiological Studies Depression scale; POMS¼Profile
of Mood States; DD¼Depression subscale of the POMS; TCA¼tricyclic antidepressant; MADRS¼Montgomery Asberg depression rating scale; CDS¼Carroll Depression Scale; DSM-IV¼Diagnostic and Statistical Manual of Mental
Disorders IV; DSM III¼Diagnostic and Statistical Manual of Mental Disorders III; HADS¼Hospital Anxiety and Depression Scale; CESD-20¼20-item Center of Epidemiological Studies Depression Scale; ES¼effect size; Dutch
POMS¼Dutch version of the shortened Profile of Mood States; GDS short version¼Geriatric Depression Scale; BDI¼Beck Depression Inventory; GHQ-28¼28-item General Health Questionnaire; GHQ-30¼30-item General
Health Questionnaire; SCL-90-R¼Symptom Checklist 90 Revised; s.d.¼standard deviation; PST¼problem-solving therapy; CBT¼cognitive behaviour therapy; PSE schedule¼Present State Examination schedule ; CNQ¼Cancer
Needs Questionnaire – short form; EORTC QLQ-30¼European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30.
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Clinical Studies(12 and 14%, respectively). Paroxetine was also found to be
effective in reducing depressive symptoms in breast cancer
patients undergoing chemotherapy (Roscoe et al, 2005).
Fluoxetine was found to be effective in reducing depressive
symptoms in patients with advanced solid tumours (Fisch et al,
2003). Frequency of vomiting was significantly higher in patients
receiving fluoxetine (nine of 27 (33%)) compared with patients
receiving placebo (two of 43 (4.6%)), but there were significantly
more fluoxetine patients receiving radiation therapy. Dropout
rates were high with 54% for the intervention group and 44% for
the controls.
There was a reduction in depressive symptoms in breast cancer
patients who received mianserin compared with those receiving
placebo (Van Heeringen and Zivkov, 1996). Tolerability appeared
to be good with no significant differences between groups for
adverse events and changes in vital signs. There were also
significantly fewer dropouts from the intervention group (21%)
when compared to controls (56%) (P¼0.014).
Psychotherapeutic studies
Characteristics of the 18 included trials of psychotherapeutic
interventions are shown in Table 1. Studies were conducted in
Europe (n¼5) (Burton et al, 1995; Marchioro et al, 1996; McArdle
et al, 1996; Moynihan et al, 1998; Kuijer et al, 2004), the United
States of America (n¼8) (Evans and Connis, 1995; Sandgren et al,
2000; Antoni et al, 2001; Classen et al, 2001; Rawl et al, 2002;
Winzelberg et al, 2003; Given et al, 2004; Weber et al, 2004)
Canada (n¼1) (Goodwin et al, 2001), Australia (n¼3) (Edelman
et al, 1999; McLachlan et al, 2001; Petersen and Quinlivan, 2002)
and Japan (n¼1) (Fukui et al, 2000). The mean sample size in the
intervention and control group was 61 patients (range 15–296)
and 52 patients (range 15–154), respectively. The average age of
patients ranged from 49 to 64 years. The proportion of female
participants ranged from between 41 to 100%. Eight studies were
multicentre trials (McArdle et al, 1996; Classen et al, 2001;
Goodwin et al, 2001; McLachlan et al, 2001; Petersen and
Quinlivan, 2002; Rawl et al, 2002; Given et al, 2004; Weber et al,
2004) and 10 were single-centre trials (Burton et al, 1995; Evans
and Connis, 1995; Marchioro et al, 1996; Moynihan et al, 1998;
Edelman et al, 1999; Fukui et al, 2000; Sandgren et al, 2000; Antoni
et al, 2001; Winzelberg et al, 2003; Kuijer et al, 2004).
Methodological quality The methodological quality of these trials
is summarised in Table 2. The sample size exceeded 100 in eight of
18 (44%) trials (Burton et al, 1995; McArdle et al, 1996; Edelman
et al, 1999; Classen et al, 2001; Goodwin et al, 2001; McLachlan
et al, 2001; Rawl et al, 2002; Given et al, 2004). All studies
randomly allocated subjects to treatment groups. Blinding of
investigators was reported in two (11%) trials (Moynihan et al,
1998; Goodwin et al, 2001). All 18 (100%) studies provided a clear
description of the intervention and had a representative source
of subjects. Reporting of attrition of subjects was provided in
16 (89%) studies and reasons for withdrawal in 13 (72%) (see
Table 1). Dropout rates for intervention and controls ranged from
0 to 41%.
In all, 17 (94%) studies were preventative, with subjects selected
on the basis of a diagnosis of cancer and only one study selected
patients with a diagnosis of depression according to DSM-III
criteria (Evans and Connis, 1995). All outcome measures were
clearly described and reliable. Only two (11%) studies avoided
some psychotherapeutic cointerventions by trial design (Goodwin
Table 2 Methodological quality of included trials summary (n¼24)
No. of pharmacological trials (%) No. of psychotherapeutic trials (%)
Quality indicator Yes, fulfilled No Unclear Yes, fulfilled No Unclear
Random allocation to treatment groups – method sufficiently described 6 (100%) — — 18 (100%) — —
Blinding of investigators 5 (83%) 1 (17%) — 2 (11%) 16 (89%) —
Blinding of subjects 6 (100%) — — — 18 (100%) —
Concealed treatment allocation 3 (50%) — 3 (50%) 6 (33%) 12 (67%)
Groups similar at baseline
Gender 5 (83%) 1 (17%) — 17 (94%) — 1 (6%)
Age 6 (100%) — — 13 (72%) 2 (11%) 3 (17%)
Ethnicity 3 (50%) — 3 (50%) 6 (33%) — 12 (67%)
Disease distribution 3 (50%) — 3 (50%) 15 (83%) 1 (6%) 2 (11%)
Cancer treatment 3 (50%) 1 (17%) 2 (33%) 10 (55%) 1 (6%) 7 (39%)
Depression/depressive symptoms 6 (100%) — — 15 (83%) — 3 (17%)
Screened for depression 4 (67%) 2 (33%) — 2 (11%) 16 (89%) —
Cointerventions
Psychotherapeutic cointerventions avoided by trial design — 6 (100%) — 2 (11%) 12 (67%) 4 (22%)
Psychotherapeutic cointerventions monitored — 6 (100%) — 5 (28%) 9 (50%) 4 (22%)
Pharmacological cointerventions avoided by trial design 5 (83%) 1 (17%) — — 18 (100%) —
Pharmacological cointerventions monitored 1 (17%) 5 (83%) — 18 (100%) —
CAM interventions for depression avoided by trial design — 6 (100%) — — 18 (100%) —
CAM interventions for depression monitored — 6 (100%) — — 18 (100%) —
Clear description of intervention 6 (100%) — — 18 (100%) — —
Outcome measures valid/reliable 6 (100%) — — 18 (100%) — —
Reporting caseness for depression at follow-up 3 (50%) 3 (50%) — 5 (28%) 13 (72%) —
Withdrawal
Attrition of subjects reported 6 (100%) — — 16 (89%) 2 (11%) —
Reasons reported 6 (100%) — — 13 (72%) 5 (28%) —
Sample size justification before study 4 (67%) 2 (33%) — 4 (22%) 14 (78%) —
No/¼100 2 (33%) 4 (67%) — 9 (50%) 9 (50%) —
Intention-to-treat analyses stated 3 (50%) 3 (50%) — 6 (33%) 12 (67%) —
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set al, 2001; Weber et al, 2004). None of the trials reported avoiding
or monitoring the use of pharmacological or CAM cointerventions.
Depression Only four of 18 (22%) trials reported the efficacy of
psychotherapeutic interventions in terms of caseness for depres-
sion (Burton et al, 1995; Moynihan et al, 1998; McLachlan et al,
2001; Petersen and Quinlivan, 2002). Of these, one found
counselling/psychotherapy to be effective in reducing caseness
for depression in breast cancer patients at 1 year follow-up
(P¼0.037; Burton et al, 1995), and another found counselling/
relaxation to be effective in reducing caseness for depression in
gynaecological cancer at 6 weeks follow-up (P¼0.0001; Petersen
and Quinlivan, 2002). Computer-based assessments and individu-
ally tailored care plans were also associated with a reduction in the
proportion of moderately or severely depressed cancer patients at
2 and 6 months follow-up (McLachlan et al, 2001); the statistical
significance of this finding was not reported. However, in men
newly diagnosed with testicular cancer, cognitive behaviour
therapy/problem-solving therapy was not found to significantly
reduce the proportion scoring above threshold for depression
(Moynihan et al, 1998).
Depressive symptoms All 18 trials (100%) reported the impact of
psychotherapeutic interventions on the level of depressive
symptoms as indicated by scores on questionnaires.
Cognitive behavioural therapy Several trials reported cognitive
behavioural therapy (CBT) to be effective. CBT was found to
reduce depressive symptoms in patients with breast, gastrointest-
inal, lymphoma, brain and lung cancers at 1 week postintervention
(ES¼0.55) (Kuijer et al, 2004), and also in depressed patients with
lung, bladder, prostate and head–neck cancers receiving radiation
treatment at 8 weeks follow-up (Po0.01) (Evans and Connis,
1995). Efficacy was also reported for women with metastatic breast
cancer immediately after completion of the intervention
(P¼0.008) (Edelman et al, 1999); women newly treated for stage
0–II breast cancer at 3 months postintervention, 6 and 12 months
(Po0.04) (Antoni et al, 2001); women with metastatic breast
cancer assessed for depressive symptoms at 4, 8 and 12 months
(ES¼0.27) (Classen et al, 2001); and in metastatic breast cancer at
1 year (P¼0.002) (Goodwin et al, 2001). In addition, one study
found CBT to have a short-term (10 weeks), but no long-term
(20 weeks), effect on depressive symptoms in patients diagnosed
with a solid tumour and receiving a first cycle of chemotherapy
(ES¼0.25 and 0.33 at 10 and 20 weeks, respectively) (Given et al,
2004). However, patients in the experimental group who entered
with higher depressive symptoms had higher levels of depressive
symptoms at 10 weeks than patients in the control group. Two
other trials found CBT to have no significant effects on depressive
symptoms in two studies of women with breast cancer (Fukui et al,
2000; Sandgren et al, 2000), but these both had sample sizes below
100 as compared to only two of the six studies that found CBT to
be effective.
Counselling/psychotherapy Counselling/psychotherapy was found
to be effective in reducing depressive symptoms in newly diagnosed
women with nonmetastatic breast cancer assigned to adjuvant
chemotherapy after surgery, with persistence over 9 months follow-
up (ES¼0.27, Marchioro et al, 1996). Counselling/relaxation was
also found to be effective in reducing mild/moderate depressive
symptoms 6 weeks after therapy in patients with gynaecological
cancer (HADS mild/moderate depression subscale, P¼0.02) but not
severe levels of depressive symptoms (GHQ-28 Major depressive
symptoms subscale, NS; Petersen and Quinlivan, 2002).
Supportive The provision of group social support was found to
be as effective as CBT in reducing depressive symptoms in
depressed patients with lung, bladder, prostate and head–neck
cancer who were receiving radiation treatment, when assessed at 8
weeks (Po0.01) and also effective at 6 months follow-up compared
with controls (Po0.01) (Evans and Connis, 1995). Peer support
from long-term survivors of prostate cancer was found to be
effective in reducing depressive symptoms in men who had
recently undergone a radical prostatectomy when assessed at 4
weeks (P¼0.02), but not at 8 weeks, follow-up (Weber et al, 2004).
A web-based social support group was also found to be effective
in reducing depressive symptoms in women with primary breast
cancer when assessed at the end of the 12 weeks intervention
(ES¼0.54) (Winzelberg et al, 2003).
In a complex trial that compared different levels of support,
routine care plus education/information/counselling/support from
breast care nurse was found to be more effective than (1) routine
care plus education/information/counselling/support from a volun-
tary organisation, (2) routine care plus education/information/
counselling/support from breast care nurse and voluntary
organisation or (3) routine care from ward staff (P¼0.015,
0.003, 0.072; McArdle et al, 1996). The failure to reduce morbidity
in the combined group is difficult to explain.
Computer-based assessments and individually tailored care
plans together with emotional support and counselling by nurses
was found to reduce depressive symptoms midway through the
intervention in newly diagnosed breast, colon or lung cancer
patients who were receiving chemotherapy (P¼0.05) (Rawl et al,
2002). Computer-based assessments and individually tailored care
plans were also found to reduce depressive symptoms (P¼0.001)
at 6 months follow-up for patients with lung, head and neck,
gynaecologic, haematology/lymphoma, melanoma and other types
of cancers unspecified in the paper (McLachlan et al, 2001).
DISCUSSION
This systematic review indicates that there is limited trial data on
the efficacy/tolerability of antidepressants and psychotherapeutic
interventions for patients with cancer and depression. The
reviewed studies varied in the type of pharmacological or
psychotherapeutic interventions employed, the characteristics of
the studied populations, the type, grade and stage of subjects’
cancer, the treatments being received, and the trial design,
including outcome measures used. Most were of small size and
lacked control for possible confounding factors. Such limitations
indicate the need for cautious interpretation of the review’s
findings beyond the contexts within which these studies were
conducted.
Pharmacological studies
Only three of the six trials that involved pharmacological
interventions reported the efficacy of antidepressants in terms of
change in caseness for clinical depression as opposed to change
scores indicating levels of depressive symptoms. Paroxetine was
found to be effective in reducing major depression in patients with
malignant melanoma who were to receive high-dose interferon
alpha therapy (Musselman et al, 2001), and in reducing caseness
for depression in breast cancer patients receiving chemotherapy
(Roscoe et al, 2005). Fluoxetine was not effective in reducing
caseness for depression in a trial that included patients with breast,
gynaecological or haematological cancer (Razavi et al, 1996).
However, the study by Razavi et al (1996) was only of brief
duration (5 weeks) and higher doses of fluoxetine were not used.
Paroxetine and fluoxetine were both effective in reducing
depressive symptoms in three trials that included patients with a
range of cancers (breast, lung, haematological, gynaecological and
gastrointestinal) (Fisch et al, 2003; Morrow et al, 2003; Roscoe
et al, 2005), and the tetracyclic antidepressant mianserin was also
Effectiveness of treatment for depression/depressive symptoms
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sshown to be effective in reducing depressive symptoms in breast
cancer (Van Heeringen and Zivkov, 1996).
Some nonpsychological benefits of antidepressant therapy also
emerged, such as improved adherence to cancer treatment. For
example, paroxetine significantly decreased the likelihood that
interferon alpha therapy in malignant melanoma would be
discontinued because of severe depression or related neurotoxic
effects (Musselman et al, 2001).
Although tolerability was only reported in four of the six
pharmacological studies, overall, the tolerability of antidepressants
in patients with cancer appears to be good. Although there was
some evidence of adverse effects, these may well have been caused
by other aspects of the treatment (e.g. radiotherapy, interferon
alpha) that these patients were receiving.
Psychotherapeutic interventions
Only four of the reviewed studies reported the efficacy of
psychotherapeutic interventions in treating depression. Of these,
two trials reported significant benefits of counselling/psycho-
therapy (Burton et al, 1995) and counselling/relaxation (Petersen
and Quinlivan, 2002) in reducing caseness for depression for
patients with breast cancer and gynaecological cancer, respectively,
and a third found computer-based assessment (including comple-
tion of the Beck Depression Inventory) and individually tailored
care plans by a nurse to be associated with a reduction in the
proportion of patients with moderate or severe depression
(McLachlan et al, 2001).
There is more extensive evidence that psychotherapeutic
interventions are effective in reducing depressive symptoms in
cancer patients, at least in the short-term. Seven trials found
cognitive behavioural therapy to be effective in reducing
depressive symptoms, with persistence of improvement demon-
strated for up to a year (Evans and Connis, 1995; Edelman et al,
1999; Antoni et al, 2001; Classen et al, 2001; Goodwin et al, 2001;
Given et al, 2004; Kuijer et al, 2004). However, two trials found
CBT to have no significant effects on depressive symptoms (Fukui
et al, 2000; Sandgren et al, 2000), and one study found CBT to have
a short-term (10 weeks), but no long-term (20 weeks), effect (Given
et al, 2004).
Other psychotherapeutic approaches that may be effective in
lowering depressive symptoms include supportive interventions in
the form of social support groups, supportive dyads or web-based
support groups (Evans and Connis, 1995; Winzelberg et al, 2003;
Weber et al, 2004), computer-based assessments and individually
tailored care plans (McLachlan et al, 2001; Rawl et al, 2002), and
counselling/psychotherapy and counselling/relaxation (Burton
et al, 1995; Marchioro et al, 1996).
Methodological limitations
A major limitation of all 24 trials reviewed was the lack of
consistent avoidance/monitoring of the use of psychotherapeutic,
pharmacological or CAM cointerventions by subjects. In general
the reviewed studies had small sample sizes, and had not
attempted to control for confounding, so limiting the validity of
findings. Many patients being treated for cancer will be receiving
care from a variety of primary-, secondary- and tertiary-care
clinicians. Many patients also make use of CAM to manage their
condition (Tatsumura et al, 2003; McClain-Jacobson et al, 2004;
Montazeri et al, 2005), and there are CAM approaches associated
with decreasing depression/depressive symptoms in cancer
patients (Targ and Levine, 2002; Fellowes et al, 2004; Cohen
et al, 2005; Rajasekaran et al, 2005). Such confounding factors can
be controlled for at the stage of data analysis, but this requires
adequate numbers of subjects to have been recruited into trials and
data on cointerventions to have been collected. While this review
was limited to non-CAM interventions, the same need for rigour
and control of confounding factors would apply to this body of
research.
A large proportion of the psychotherapeutic studies were single-
centre trials, so limiting the generalisability of findings beyond the
context of the trial setting. Psychotherapeutic interventions are
likely to be highly dependent on the practitioners’ training, skills
and other attributes. Hence, multicentre trials are needed to
confirm the applicability and effectiveness of interventions.
Furthermore, many of the studies report findings that only just
achieve statistical significance, suggesting the likelihood of
publication bias that needs to be considered in the interpretation
of their findings.
There was only one trial that selected patients on the basis of a
diagnosis of depression (Evans and Connis, 1995), but the change
in caseness for depression was not reported in this study. The
negative findings of some studies may reflect that recruited
subjects did not have significant psychological morbidity; psycho-
therapeutic and pharmacological interventions should be offered
to patients with clinically meaningful levels of depression/
depressive symptoms.
Given the small number of studies on the efficacy on
antidepressants with cancer patients in general, there is a need
for further work with specific groups of cancer patients.
Tolerability data were not always recorded and reported. It is
important that future studies include recording and reporting of
adverse effects, especially as such effects are likely to have an
impact on compliance (Stokes, 1993). Concerns that antidepres-
sants may lead to or accelerate the development of cancer also
need further investigation (Brandes et al, 1992; Wallace et al,
2001).
Finally, while the randomised controlled studies in this review
may be of relevance to palliative care, no studies were conducted
with palliative care patients as subjects. Controlled studies
including such subjects are even more difficult to conduct than
those on nonpalliative cancer patients. Depression is difficult to
diagnose in such patients, and depressive symptoms are very
similar to the general symptoms of end-stage cancer. While high
attrition rates, together with high heterogeneity, would lead to the
need for very large sample sizes, recruitment is difficult for
practical and ethical reasons (Grande and Todd, 2000; Addington-
Hall, 2002). There is also a lack of reporting on syndromal
depression and this too requires further work.
CONCLUSION
The sparse number of studies of pharmacological interventions for
cancer patients with depression provides some evidence that
antidepressants are effective in reducing depression/depressive
symptoms in cancer patients. Although more data are needed
regarding the safety and efficacy of antidepressants, there is some
evidence that cancer patients with depression are responsive to
treatment. Overall, the small number of trials of pharmacological
interventions for cancer patients with depression/depressive
symptoms, high dropout rates in some trials and lack of reporting
of adverse events/tolerability should caution against drawing
definitive conclusions about which antidepressants are most
effective or well tolerated by cancer patients in general or by
patients with specific types of cancer.
There is limited trial data on the efficacy of psychotherapeutic
interventions in treating depression/depressive symptoms in
cancer patients. Cognitive behavioural therapy appears to be
effective in reducing depressive symptoms in cancer patients.
Social support for cancer patients may also be effective in reducing
depressive symptoms.
However, there is a need for more rigorous investigation of the
efficacy of both pharmacological and psychotherapeutic interven-
tions, including avoidance/monitoring of the confounding factors
Effectiveness of treatment for depression/depressive symptoms
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sof the use of other pharmacological/psychotherapeutic and CAM
cointerventions by subjects. In addition, there is also a need for
studies comparing the efficacy of psychotherapeutic vs pharma-
cological interventions. With the known side effects and the
controversies about the possible stimulation of malignant growth
by antidepressant drugs, there is a need for careful and rigorous
investigation of the efficacy of pharmacological treatment for
depression in cancer patients and more importantly of possible
psychotherapeutic alternatives (Wallace et al, 2001).
Finally, the current lack of clinical trial data to robustly
demonstrate efficacy is not synonymous with evidence of
ineffectiveness. It would be entirely inappropriate to use the
findings of this review to deny patients with cancer access to
treatment for depression and depressive symptoms because of a
lack of trial data on effectiveness. The review indicates that there
remains a pressing need for more thorough and extensive
investigation of the effectiveness and consequences of different
approaches to managing depression in cancer patients to inform
the design and delivery of effective healthcare services.
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Data Extraction Form Methodological Quality Instrument (Cho and Bero, 1994) (Table A1).
Table A1
Reviewer _________
Article _________
1. Study design (choose 1 only):
Experimental randomised:
______ Placebo-controlled trial
______ Controlled trial
______ Comparative trial, no placebo
______ Time series trial
______ Crossover trial
Experimental, unrandomised:
______ Placebo controlled trial
______ Comparative trial, no placebo
______ Time series trial
______ Crossover trial
______ Natural experiment
Nonexperimental:
______ Cohort, prospective
______ Cohort, retrospective
______ Cross-sectional
______ Case–control
______ Case reports or case series
______ None of the above (describe):
2. What was the study question? (please use space below)
Yes Partial No N/A
3. Was the study question sufficiently described?
4. Was the study design appropriate to answer the study question?
5. Were both inclusion and exclusion criteria specified? (If case study, check N/A)
6. For case studies only: Were patient characteristics adequately reported? (If not case study, check N/A.)
7. Were subjects appropriate to the study question?
8. Were control subjects appropriate? (If no controls were used, check No).
9. Were subjects randomly selected from the target population?
10. If subjects were randomly selected, was the method of random selection sufficiently
well described? (If subjects were not randomly selected, check N/A).
11. If subjects were randomly allocated to treatment groups, was the method of random
allocation sufficiently described? (If subjects were not randomly allocated, check N/A).
12. If blinding of investigators to intervention was possible, was it reported? (If not possible check N/A).
13. If blinding of subjects to intervention was possible, was it reported? (If not possible, check N/A).
14. Was measurement bias accounted for by methods other than blinding?
15. Were known confounders accounted for by study design? (If no known confounders, check N/A).
16. Were known confounders accounted for by analysis? (If no known confounders, check N/A).
17. Was there a sample size justification before the study?
18. Were post hoc power calculations or confidence intervals reported for statistically nonsignificant results?
19. Were statistical analyses appropriate?
20. Were statistical tests stated?
21. Were exact P values or confidence intervals reported for each test?
22. Were attrition of subjects and reason for attrition recorded?
23. For those subjects who completed the study, were results completely reported?
24. Do the findings support the conclusions?
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Table A2
Reviewer: Authors/date Country of origin:
Study details Yes No Unclear
Patient groups similar at baseline? No sig. diffs. Gender
Age
Ethnicity
Disease distribution
Cancer treatment
Depression/Depressive symptoms
Setting/s
Screening/diagnostic procedure for depression or depressive symptoms
(consider issues for access to healthcare treatment)
Intervention treatment
1. Description of intervention and implementation?
2. Measure of compliance?
3. Cointerventions: avoided by trial design/monitored
(Also consider issues for access to healthcare treatment)
Possible adverse effects
Use of diagnostic criteria for depression?
Outcome measures used (adequately described, valid/reliable?)
Dropout rates and reasons for withdrawal
Noneligible patients
See table
Data analysis Yes No Unclear
Economic analysis as part of trial?
Conclusion
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